aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Aardvark Therapeutics is a clinical stage biopharmaceutical company dedicated to developing novel small molecule therapeutics aimed at activating innate homeostatic pathways. The company's primary focus is on treating metabolic diseases and inflammation through innovative approaches that leverage gut-brain signaling. Their research centers on bitter taste receptors (Tas2Rs), a class of GPCRs with broad therapeutic potential.
Aardvark Therapeutics has made significant strides in the biopharmaceutical field by advancing its unique science and achieving incomparable results. Their commitment to developing safe and effective treatments has positioned them as a key player in addressing complex metabolic and inflammatory conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Aardvark Therapeutics founded?
Aardvark Therapeutics was founded in 2017.
Where is Aardvark Therapeutics’s headquarters located?
Aardvark Therapeutics’s headquarters is located in San Diego, CA, US.
When was Aardvark Therapeutics’s last funding round?
Aardvark Therapeutics’s most recent funding round was for $29M (USD) in August 2021.
How many employees does Aardvark Therapeutics have?
Aardvark Therapeutics has 38 employees as of Feb 5, 2024.
How much has Aardvark Therapeutics raised to-date?
As of July 05, 2023, Aardvark Therapeutics has raised a total of $44M (USD) since Aug 5, 2021.
Add Comparison
Total Raised to Date
$44M
USD
Last Update Aug 5, 2021
Last Deal Details
$29M
USD
Aug 5, 2021
Series B
Total Employees Over Time
38
As of Feb 2024
Aardvark Therapeutics Address
12707 High Bluff Drive
suite 200
San Diego,
California
92130
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts